scholarly journals The effect of neoadjuvant chemotherapy among patients undergoing radical cystectomy for variant histology bladder cancer: A systematic review

2021 ◽  
pp. 1-13
Author(s):  
Mario Alvarez-Maestro ◽  
Francesco Chierigo ◽  
Guglielmo Mantica ◽  
J. M. Quesada-Olarte ◽  
D. M. Carrion ◽  
...  
Keyword(s):  
Systematic Review ◽  
Bladder Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Radical Cystectomy ◽  
Variant Histology

scholarly journals Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology

Cancer ◽  
2017 ◽  
Vol 123 (22) ◽  
pp. 4346-4355 ◽  
Author(s):  
Malte W. Vetterlein ◽  
Stephanie A. M. Wankowicz ◽  
Thomas Seisen ◽  
Richard Lander ◽  
Björn Löppenberg ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Radical Cystectomy ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Variant Histology ◽  
Muscle Invasive

scholarly journals MP34-11 NEOADJUVANT CHEMOTHERAPY PRIOR TO RADICAL CYSTECTOMY FOR MUSCLE-INVASIVE BLADDER CANCER WITH VARIANT HISTOLOGY

2017 ◽  
Vol 197 (4S) ◽  
Author(s):  
Malte W. Vetterlein ◽  
Stephanie Mullane ◽  
Thomas Seisen ◽  
Richard Lander ◽  
Björn Löppenberg ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Radical Cystectomy ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Variant Histology ◽  
Muscle Invasive

scholarly journals Efficient delivery of radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer

Cancer ◽  
2011 ◽  
Vol 118 (1) ◽  
pp. 44-53 ◽  
Author(s):  
Ajjai S. Alva ◽  
Christopher T. Tallman ◽  
Chang He ◽  
Maha H. Hussain ◽  
Khaled Hafez ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Radical Cystectomy ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Efficient Delivery ◽  
Muscle Invasive

scholarly journals Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study

PLoS Medicine ◽  
2021 ◽  
Vol 18 (8) ◽  
pp. e1003732
Author(s):  
Pradeep S. Chauhan ◽  
Kevin Chen ◽  
Ramandeep K. Babbra ◽  
Wenjia Feng ◽  
Nadja Pejovic ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Radical Cystectomy ◽  
Residual Disease ◽  
Muscle Invasive Bladder Cancer ◽  
Curative Intent ◽  
Muscle Invasive ◽  
Bladder Sparing ◽  
Tumor Dna ◽  
Minimal Residual

Background The standard of care treatment for muscle-invasive bladder cancer (MIBC) is radical cystectomy, which is typically preceded by neoadjuvant chemotherapy. However, the inability to assess minimal residual disease (MRD) noninvasively limits our ability to offer bladder-sparing treatment. Here, we sought to develop a liquid biopsy solution via urine tumor DNA (utDNA) analysis. Methods and findings We applied urine Cancer Personalized Profiling by Deep Sequencing (uCAPP-Seq), a targeted next-generation sequencing (NGS) method for detecting utDNA, to urine cell-free DNA (cfDNA) samples acquired between April 2019 and November 2020 on the day of curative-intent radical cystectomy from 42 patients with localized bladder cancer. The average age of patients was 69 years (range: 50 to 86), of whom 76% (32/42) were male, 64% (27/42) were smokers, and 76% (32/42) had a confirmed diagnosis of MIBC. Among MIBC patients, 59% (19/32) received neoadjuvant chemotherapy. utDNA variant calling was performed noninvasively without prior sequencing of tumor tissue. The overall utDNA level for each patient was represented by the non-silent mutation with the highest variant allele fraction after removing germline variants. Urine was similarly analyzed from 15 healthy adults. utDNA analysis revealed a median utDNA level of 0% in healthy adults and 2.4% in bladder cancer patients. When patients were classified as those who had residual disease detected in their surgical sample (n = 16) compared to those who achieved a pathologic complete response (pCR; n = 26), median utDNA levels were 4.3% vs. 0%, respectively (p = 0.002). Using an optimal utDNA threshold to define MRD detection, positive utDNA MRD detection was highly correlated with the absence of pCR (p < 0.001) with a sensitivity of 81% and specificity of 81%. Leave-one-out cross-validation applied to the prediction of pathologic response based on utDNA MRD detection in our cohort yielded a highly significant accuracy of 81% (p = 0.007). Moreover, utDNA MRD–positive patients exhibited significantly worse progression-free survival (PFS; HR = 7.4; 95% CI: 1.4–38.9; p = 0.02) compared to utDNA MRD–negative patients. Concordance between urine- and tumor-derived mutations, determined in 5 MIBC patients, was 85%. Tumor mutational burden (TMB) in utDNA MRD–positive patients was inferred from the number of non-silent mutations detected in urine cfDNA by applying a linear relationship derived from The Cancer Genome Atlas (TCGA) whole exome sequencing of 409 MIBC tumors. We suggest that about 58% of these patients with high inferred TMB might have been candidates for treatment with early immune checkpoint blockade. Study limitations included an analysis restricted only to single-nucleotide variants (SNVs), survival differences diminished by surgery, and a low number of DNA damage response (DRR) mutations detected after neoadjuvant chemotherapy at the MRD time point. Conclusions utDNA MRD detection prior to curative-intent radical cystectomy for bladder cancer correlated significantly with pathologic response, which may help select patients for bladder-sparing treatment. utDNA MRD detection also correlated significantly with PFS. Furthermore, utDNA can be used to noninvasively infer TMB, which could facilitate personalized immunotherapy for bladder cancer in the future.

A systematic review and meta-analysis of lymphovascular invasion in patients treated with radical cystectomy for bladder cancer

2018 ◽  
Vol 36 (6) ◽  
pp. 293-305 ◽  
Author(s):  
Andrea Mari ◽  
Shoji Kimura ◽  
Beat Foerster ◽  
Mohammad Abufaraj ◽  
David D'Andrea ◽  
...  
Keyword(s):  
Systematic Review ◽  
Bladder Cancer ◽  
Radical Cystectomy ◽  
Lymphovascular Invasion ◽  
Meta Analysis

Oncologic Surveillance for Variant Histology Bladder Cancer after Radical Cystectomy

2021 ◽  
Author(s):  
Alberto Martini ◽  
Luca Afferi ◽  
Stefania Zamboni ◽  
Julianne G. Schultz ◽  
Chiara Lonati ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Radical Cystectomy ◽  
Variant Histology
Sign in / Sign up

Export Citation Format

Share Document